Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Terminated 4Recruiting 4Not yet recruiting 2Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Neoplasms 3Breast Neoplasms 2Anorexia 2Vomiting 1Neoplasms, Second Primary 1Mesothelioma, Malignant 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Cachexia 1

Interventions

Paclitaxel 6Carboplatin 6Radiotherapy 5olaparib 4Surveys and Questionnaires 4Cisplatin 4Surgical Procedures, Operative 3Sentinel Lymph Node Biopsy 3Metformin 3pembrolizumab 2lenvatinib 2durvalumab 2dostarlimab 2anlotinib 2Reverse Transcriptase Polymerase Chain Reaction 2Progesterone 2Magnetic Resonance Spectroscopy 2Injections 2High-Energy Shock Waves 2Hematologic Tests 2Genetic Testing 2Docetaxel 2Blood Specimen Collection 2Base Sequence 2Amplified Fragment Length Polymorphism Analysis 2vistusertib 1serabelisib 1pazopanib 1palbociclib 1onapristone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Endometrial Neoplasms × Megestrol Acetate × Clear all
NCT00002465 2013-11-06

High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Unknown
BreastGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡